|
|
Hardman & Co Research
Hardman & Co Research: Oxford BioMedica OXB: Demanding second half 16Oct2019 / 07:30 GMT/BST
Hardman & Co Research: Demanding second half
Oxford BioMedica OXB is a genebased medicine viralvector biopharma company. It offers vector manufacturing and development services, while developing proprietary therapies, with its LentiVectorR platform. Growth in gross income and... See more |
|
|
|
| |
|
| |
|
|
CWT
CWT appoints John Pelant as Chief Technology Officer 16Oct2019 / 07:00 GMT/BST
CWT appoints John Pelant as Chief Technology Officer
Minneapolis, 16 October 2019: CWT, the B2B4E travel management platform, today announces the appointment of John Pelant as Executive Vice President and Chief Technology Officer, with effect from 1 November 2019. Based in Minneapolis, John will... See more |
|
|
|
| |
|
| |
|
|
Polymetal International plc POLY
Polymetal: 10year credit facility with Sberbank 16Oct2019 / 09:00 MSK
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Release time
IMMEDIATE... See more |
|
|
|
| |
|
| |
|
|
PRESS RELEASE
October 16, 2019
PRESS RELEASE
SAINT-GOBAIN ACCELERATES ITS DEVELOPMENT IN MORTARS IN PERU
Saint-Gobain has just closed the acquisition of 100% of the mortars division of
the Celima group in Peru, a market where Saint-Gobain has been present since
2014 through its Weber... See more |
|
|
|
| |
|
| |
|
|
EQS GroupAdhoc: Conzzeta / Schlagworte: 9Monatszahlen
Conzzeta: Q3 mit tieferem Umsatz Aufträge auf Höhe Vorjahr
16.10.2019 / 07:00 CET/CEST
Veröffentlichung einer AdhocMitteilung gemäss Art. 53 KR
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Zwischeninformation per Ende 3. Quartal 2019Q3 mit tieferem Umsatz Aufträge auf... See more |
|
|
|
| |
|
| |
|
|
EQS GroupAdhoc: Conzzeta / Key words: 9 Month figures
Conzzeta: Revenue lower in Q3 orders at previous years level
16Oct2019 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Interim information as of the end of Q3 2019Revenue lower in Q3 orders at previous years level
Zurich, October 16, 2019 ... See more |
|
|
|
| |
|
| |
|
|
Montrouge, France, October 15, 2019
DBV Technologies Announces Closing of Global
Offering
DBV Technologies the “Company” Euronext: DBV – ISIN: FR0010417345 – Nasdaq
Stock Market: DBVT, a clinicalstage biopharmaceutical company, today
announced the settlement and delivery on October 11, 2019 of an underwritten
global offering of an aggregate of 9,484,066 ordinary shares reserved to... See more |
|
|
|
| |
|
| |
|
|
Montrouge, France, le 15 octobre 2019, 22h30 CET
DBV Technologies annonce la réalisation de son offre
globale
DBV Technologies la « Société » Euronext : DBV – ISIN : FR0010417345 – Nasdaq
Stock Market : DBVT, société biopharmaceutique française, annonce ce jour le
règlementlivraison intervenu le 11 octobre 2019, de son offre globale dun total de
9.484.066 actions ordinaires... See more |
|
|
|
| |
|
| |
